SPECT Versus PET for [177Lu]Lu-PSMA Response Assessment Using Quantitative RECIP 1.0 - PubMed
7 hours ago
- #PSMA
- #SPECT
- #PET
- Comparison of SPECT/CT and PET/CT for response assessment in [177Lu]Lu-PSMA therapy for metastatic castration-resistant prostate cancer (mCRPC).
- Study included 102 patients undergoing both SPECT/CT and PET/CT imaging for response evaluation using RECIP 1.0 criteria.
- Substantial agreement (κ = 0.67) between SPECT and PET for identifying progressive disease, improving to κ = 0.93 when combined with PSA measures.
- Progressive disease identified by either modality was associated with shorter progression-free survival (PFS) and overall survival (OS).
- PET provided higher prognostic accuracy for PFS than SPECT, but comparable for OS.
- SPECT response excluded progression on PET, and SPECT progression was always confirmed by PET.
- Findings support the use of cycle 2 SPECT/CT for early response assessment in [177Lu]Lu-PSMA therapy.